Disruptive Technology Channel ARKG: Smart Idea for Smart Advancements in Cancer Treatment By Tom LydonApril 24, 2023
ETF Building Blocks Channel Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
Disruptive Technology Channel Innovation Is Crucial to Healthcare Sector Long-Term Growth By Tom LydonMarch 23, 2023
Disruptive Technology Channel Outlook for Healthcare Innovation Is Brightening By Tom LydonMarch 17, 2023
Disruptive Technology Channel These Segments Could Power ARK Genomics ETF By Tom LydonFebruary 24, 2023
Disruptive Technology Channel Bright Future for this Disruptive Healthcare ETF By Tom LydonFebruary 21, 2023
Disruptive Technology Channel Eye DNA Synthesis Advances in Active Biotech ETF ARKG By Nick Peters-GoldenFebruary 1, 2023
Disruptive Technology Channel Get Benefits From Innovator ACCD in Health Tech ETF ARKG By Nick Peters-GoldenJanuary 18, 2023
Disruptive Technology Channel EXAS Nears Key Buy Signal in Active Biotech ETF ARKG By Nick Peters-GoldenJanuary 11, 2023
Disruptive Technology Channel Why Now Could Be Time to Buy No Cap Gain ARK Strats By Nick Peters-GoldenDecember 30, 2022
Disruptive Technology Channel ARK Continues Contrarian Plays in ETFs TSLA, COIN, VERV By Nick Peters-GoldenDecember 16, 2022
Disruptive Technology Channel Gene Editing Stock in ARKG Gets Buy Rating By Nick Peters-GoldenDecember 14, 2022
Disruptive Technology Channel Why a Biotech ETF Might Cure Your Portfolio in 2023 By Nick Peters-GoldenDecember 7, 2022
Disruptive Technology Channel Why This Biotech Firm is the Top Weight in ARKG By Nick Peters-GoldenNovember 28, 2022
Disruptive Technology Channel ARK Completes Move to Florida With Broad Research Team By Todd RosenbluthNovember 22, 2022
Disruptive Technology Channel ARK Partners With BMO to Bring ARK Funds to Canada By Nick Peters-GoldenNovember 18, 2022
